News

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Pharmaceutical Technology on MSN2d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
Fierce Pharma2d
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
NJBIZ3d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...
The Economist2d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...